Strong growth in license revenues and partnerships with major MedTech firms drive a 48% Q3 net sales increase and improved EBITDA. Advanced infection prevention technology shows 70% risk reduction and supports expansion across multiple therapeutic areas.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.